Zacks Investment Research on MSN2d
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
pharmaphorum3d
Phase 3 readout puts Opthea at risk of insolvency
Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.
Nasdaq1mon
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).
pharmaphorum10y
Eylea beats rivals in government-sponsored head-to-head trial
Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...
Medscape9y
Eylea vs Lucentis for Treatment-Naive Neovascular AMD
Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...